SCHEMBL2015049

SCHEMBL2015049

CC(=O)c1cnn(C)c1Cl

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.45
ALDH1A1 P00352 4/20 0.40
KDM4E B2RXH2 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
SMN1; SMN2 Q16637 6/20 0.39
RAB9A P51151 4/20 0.39
NPC1 O15118 2/20 0.39
HTT P42858 2/20 0.39
MAPT P10636 3/20 0.36
CYP1A2 P05177 2/20 0.36
HPGD P15428 1/20 0.36
KAT2B Q92831 1/20 0.36
BRD9 Q9H8M2 1/20 0.36
ADORA1 P30542 1/20 0.36
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
LMNA P02545 2/20 0.34
CYP2D6 P10635 1/20 0.34
CYP2C19 P33261 1/20 0.34
TP53 P04637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL966692 0.83 KDM4E (0.41) ALDH1A1KDM4ETDP1SMN1; SMN2RAB9A
SCHEMBL5204576 0.83 TSHR (0.44) ALDH1A1KDM4ETDP1SMN1; SMN2RAB9A
SCHEMBL619113 0.83 HTT (0.36) MAPK1ALDH1A1SMN1; SMN2RAB9ANPC1
SCHEMBL26677700 0.80 KAT2B (0.51) MAPK1ALDH1A1RAB9AMAPTKAT2B
SCHEMBL9204354 0.79 CYP1A2 (0.44) ALDH1A1KDM4ERAB9ANPC1CYP1A2
SCHEMBL1641560 0.78 SMN1; SMN2 (0.54) MAPK1ALDH1A1KDM4ETDP1SMN1; SMN2
SCHEMBL21938820 0.78 MAPK1 (0.41) MAPK1ALDH1A1KDM4ETDP1SMN1; SMN2
SCHEMBL11965637 0.77 MAPK1 (0.40) MAPK1ALDH1A1KDM4ETDP1SMN1; SMN2
SCHEMBL19166978 0.75 ALDH1A1 (0.45) MAPK1ALDH1A1KDM4ETDP1SMN1; SMN2
SCHEMBL24567566 0.74 ACACB (0.42) ALDH1A1KDM4ESMN1; SMN2RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7964732-B2 Substituted bicyclocarboxyamide compounds PFIZER INC. (US) 2011-06-21 US disclosed
US-20100267769-A1 Substituted Bicyclocarboxyamide Compounds Pfizer, Inc. and Renovis Inc. 2010-10-21 US disclosed
EP-2091944-A2 SUBSTITUTED BICYCLOCARBOXYAMIDE COMPOUNDS Pfizer, Inc. (US) 2009-08-26 EP disclosed
WO-2008059370-A2 SUBSTITUTED BICYCLOCARBOXYAMIDE COMPOUNDS PFIZER JAPAN INC. (JP) 2008-05-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100267769-A1 Substituted Bicyclocarboxyamide Compounds TRPV1, OPRL1, CNR1 MAPK1 952/4885ALDH1A1 1305/4885KDM4E 4164/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.